drugset
drugset / Trial / NCT05381454

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

NCT05381454 ↗

Phase 1/2 Completed 80 enrolled University of California, Los Angeles
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Open label clinical trial of persons (adults) that will determine the safety and efficacy of the diet supplement oral mitoquinone/mitoquinol mesylate (Mito-MES) to prevent the development and progression of severe viral infections like COVID-19 after high-risk exposure to a person with possible respiratory viral infection such as SARS-CoV-2 infection in persons who will receive Mito-MES compared to persons who will not receive Mito-MES (controls).

Timeline

Start
2022-04-28
Primary completion
2023-05-09
Completion
2023-05-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MitoQ Small molecule 20 mg Oral

Indications

COVID-19 viral respiratory tract infection